IgA肾病的免疫抑制治疗进展
Progress in Immunosuppressive Therapy for IgA Nephropathy
DOI: 10.12677/acm.2026.162412, PDF,   
作者: 赵 若, 廖晓辉*：重庆医科大学附属第二医院肾内科，重庆
关键词: IgA肾病；发病机制；免疫抑制治疗；IgA Nephropathy； Pathogenesis； Immunosuppressive Therapy
摘要: IgA肾病(IgA nephropathy, IgAN)作为全球最常见的原发性肾小球疾病，是中青年人群发生终末期肾病的重要病因，对全球公共卫生构成显著负担。该病临床表现异质性高，发病机制尚未完全阐明，长期以来缺乏特异性的病因治疗手段。2025年KDIGO临床实践指南进一步严格了蛋白尿的控制目标，并突出强调了靶向治疗在疾病管理中的关键地位。近年来，针对其免疫发病机制中不同环节的多种靶向药物相继进入临床研究阶段，标志着IgAN的治疗策略正从传统的非特异性免疫抑制，逐步转向基于病理机制的精准靶向干预。本文旨在系统综述免疫抑制治疗在IgAN中的最新研究进展。
Abstract: IgA nephropathy (IgAN), as the most common primary glomerular disease worldwide, is an important cause of end-stage renal disease in young and middle-aged people, posing a significant burden on global public health. The clinical manifestations of this disease are highly heterogeneous, and its pathogenesis has not been fully elucidated. For a long time, there has been a lack of specific etiological treatment methods. The 2025 KDIGO Clinical Practice Guideline further tightened the control target of proteinuria and highlighted the crucial role of targeted therapy in disease management. In recent years, a variety of targeted drugs aiming at different links in its immune pathogenesis have successively entered the clinical research stage, indicating that the treatment strategy of IgAN is gradually shifting from traditional non-specific immunosuppression to precise targeted intervention based on pathological mechanisms. This article aims to systematically review the latest research progress of immunosuppressive therapy in IgAN.
文章引用：赵若, 廖晓辉. IgA肾病的免疫抑制治疗进展[J]. 临床医学进展, 2026, 16(2): 440-447. https://doi.org/10.12677/acm.2026.162412

参考文献

[1] Berger, J. and Hinglais, N. (1968) Intercapillary Deposits of IgA-IgG. Journal of Urology and Nephrology (Paris), 74, 694-695.
[2] Schena, F.P. and Nistor, I. (2018) Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 38, 435-442. [Google Scholar] [CrossRef] [PubMed]
[3] DʼAmico, G., Imbasciati, E., DI Belgioioso, G.B., Bertoli, S., Fogazzi, G., Ferrario, F., et al. (1985) Idiopathic IgA Mesangial Nephropathy. Clinical and Histological Study of 374 Patients Medicine, 64, 49-60. [Google Scholar] [CrossRef] 
[4] Yeo, S.C., Goh, S.M. and Barratt, J. (2019) Is Immunoglobulin a Nephropathy Different in Different Ethnic Populations? Nephrology, 24, 885-895. [Google Scholar] [CrossRef] [PubMed]
[5] Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology, 22, 1795-1803. [Google Scholar] [CrossRef] [PubMed]
[6] Pereira, I.M., Pereira, M., Lopes, J.A. and Gameiro, J. (2024) The Gut Microbiome as a Potential Therapeutic Target in IgA Nephropathy. Nephrology Dialysis Transplantation, 40, 641-650. [Google Scholar] [CrossRef] [PubMed]
[7] Toal, M.P., Hill, C.J., Quinn, M.P., McQuarrie, E.P., O’Neill, C.E. and Maxwell, A.P. (2024) An International Study of Variation in Attitudes to Kidney Biopsy Practice. Clinical Journal of the American Society of Nephrology, 20, 377-386. [Google Scholar] [CrossRef] [PubMed]
[8] Zhao, J., Bai, M., Ning, X., Qin, Y., Wang, Y., Yu, Z., et al. (2022) Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy. Journal of the American Society of Nephrology, 33, 2276-2292. [Google Scholar] [CrossRef] [PubMed]
[9] Floege, J., Barratt, J., Cook, H.T., Noronha, I.L., Reich, H.N., Suzuki, Y., et al. (2025) Executive Summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin a Nephropathy (IgAN) and Immunoglobulin a Vasculitis (IgAV). Kidney International, 108, 548-554. [Google Scholar] [CrossRef] 
[10] Caster, D.J. and Lafayette, R.A. (2024) The Treatment of Primary IgA Nephropathy: Change, Change, Change. American Journal of Kidney Diseases, 83, 229-240. [Google Scholar] [CrossRef] [PubMed]
[11] Wong, M.G., Lv, J., Hladunewich, M.A., Jha, V., Hooi, L.S., Monaghan, H., et al. (2021) The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 52, 827-836. [Google Scholar] [CrossRef] [PubMed]
[12] 中国IgA肾病协作组(IIgANN⁃China)科学委员会中华预防医学会肾脏病预防与控制专业委员会. 中国成人IgA肾病及IgA血管炎肾炎临床实践指南(2025) [J]. 中华内科杂志, 2025, 64(10): 918-944.
[13] Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G.B., Altieri, P., et al. (2004) Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial. Journal of the American Society of Nephrology, 15, 157-163. [Google Scholar] [CrossRef] [PubMed]
[14] Weng, Q., Ouyang, Y., Chen, Z., Jin, Y., Xu, J., Liu, J., et al. (2025) Efficacy and Safety of Telitacicept in IgA Nephropathy: Real-World Study Outcomes. Clinical Kidney Journal, 18, sfaf154. [Google Scholar] [CrossRef] [PubMed]
[15] Lafayette, R., Kristensen, J., Stone, A., Floege, J., Tesař, V., Trimarchi, H., et al. (2023) Efficacy and Safety of a Targeted-Release Formulation of Budesonide in Patients with Primary IgA Nephropathy (NefIgArd): 2-Year Results from a Randomised Phase 3 Trial. The Lancet, 402, 859-870. [Google Scholar] [CrossRef] [PubMed]
[16] Fellström, B.C., Barratt, J., Cook, H., Coppo, R., Feehally, J., de Fijter, J.W., et al. (2017) Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127. [Google Scholar] [CrossRef] [PubMed]
[17] Barratt, J., Lafayette, R., Kristensen, J., Stone, A., Cattran, D., Floege, J., et al. (2023) Results from Part a of the Multi-Center, Double-Blind, Randomized, Placebo-Controlled NefIgArd Trial, Which Evaluated Targeted-Release Formulation of Budesonide for the Treatment of Primary Immunoglobulin a Nephropathy. Kidney International, 103, 391-402. [Google Scholar] [CrossRef] [PubMed]
[18] Hou, F.F., Xie, D., Wang, J., Xu, X., Yang, X., Ai, J., et al. (2023) Effectiveness of Mycophenolate Mofetil among Patients with Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Network Open, 6, e2254054. [Google Scholar] [CrossRef] [PubMed]
[19] Ngai, C., Pesce, G., Zaidi, S., Petiot, N., Tolouian, R. and Madison, T. (2024) Results from a Real-World Case Series of Patients with IgAN Who Received at Least 9 Months of Tarpeyo. Journal of the American Society of Nephrology, 35. [Google Scholar] [CrossRef] 
[20] Lafayette, R., Jones, R. and Mitchev, K. (2025) #3337 The NefXtend Trial, Investigating Extended Nefecon Treatment beyond 9 Months in Patients with IgAN. Nephrology Dialysis Transplantation, 40, gfaf116.0270. [Google Scholar] [CrossRef] 
[21] Dang, S., Zhang, X., Zhang, Y. and Zhang, H. (2025) New Thoughts on the Intestinal Microbiome-B Cell-IgA Axis and Therapies in IgA Nephropathy. Autoimmunity Reviews, 24, Article ID: 103835. [Google Scholar] [CrossRef] [PubMed]
[22] Sastre, D.E., Bournazos, S., Du, J., Boder, E.J., Edgar, J.E., Azzam, T., et al. (2024) Potent Efficacy of an IgG-Specific Endoglycosidase against IgG-Mediated Pathologies. Cell, 187, 6994-7007.e12. [Google Scholar] [CrossRef] [PubMed]
[23] Jordan, S.C., Lorant, T., Choi, J., Kjellman, C., Winstedt, L., Bengtsson, M., et al. (2017) IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. New England Journal of Medicine, 377, 442-453. [Google Scholar] [CrossRef] [PubMed]
[24] Xie, X., Li, J., Liu, P., Wang, M., Gao, L., Wan, F., et al. (2022) Chimeric Fusion between Clostridium Ramosum IgA Protease and IgG Fc Provides Long-Lasting Clearance of IgA Deposits in Mouse Models of IgA Nephropathy. Journal of the American Society of Nephrology, 33, 918-935. [Google Scholar] [CrossRef] [PubMed]
[25] 傅子晋, 傅大煦. 补体系统药物在IgA肾病中的研究与应用进展[J]. 国际生物制品学杂志, 2025, 48(2): 146-153.
[26] McCoy, R.C., Abramowsky, C.R. and Tisher, C.C. (1974) IgA Nephropathy. The American Journal of Pathology, 76, 123-144.
[27] Bene, M.C. and Faure, G.C. (1987) Composition of Mesangial Deposits in IgA Nephropathy: Complement Factors. Nephron, 46, Article No. 219. [Google Scholar] [CrossRef] [PubMed]
[28] Maillard, N., Wyatt, R.J., Julian, B.A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., et al. (2015) Current Understanding of the Role of Complement in IgA Nephropathy. Journal of the American Society of Nephrology, 26, 1503-1512. [Google Scholar] [CrossRef] [PubMed]
[29] Lafayette, R.A., Rovin, B.H., Reich, H.N., Tumlin, J.A., Floege, J. and Barratt, J. (2020) Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of Iga Nephropathy. Kidney International Reports, 5, 2032-2041. [Google Scholar] [CrossRef] [PubMed]
[30] Omeros Corporation (2023) Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy.
[31] Zhang, H., Rizk, D.V., Perkovic, V., Maes, B., Kashihara, N., Rovin, B., et al. (2024) Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study Propose Iptacopan as an Alternative Complement Pathway Inhibitor for IgA Nephropathy. Kidney International, 105, 189-199. [Google Scholar] [CrossRef] [PubMed]
[32] Novartis (2023) Novartis Investigational Atrasentan Phase III Study Demonstrates Clinically Meaningful and Highly Statistically Significant Proteinuria Reduction in Patients with IgA Nephropathy (IgAN).
[33] Jayne, D.R.W., Bruchfeld, A.N., Harper, L., Schaier, M., Venning, M.C., Hamilton, P., et al. (2017) Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology, 28, 2756-2767. [Google Scholar] [CrossRef] [PubMed]
[34] Lafayette, R., Tumlin, J., Fenoglio, R., Kaufeld, J., Pérez Valdivia, M.Á., Wu, M., et al. (2024) Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. Journal of the American Society of Nephrology, 36, 645-656. [Google Scholar] [CrossRef] [PubMed]
[35] Bruchfeld, A., Magin, H., Nachman, P., Parikh, S., Lafayette, R., Potarca, A., et al. (2022) C5a Receptor Inhibitor Avacopan in Immunoglobulin a Nephropathy—An Open-Label Pilot Study. Clinical Kidney Journal, 15, 922-928. [Google Scholar] [CrossRef] [PubMed]
[36] Shabgah, A.G., Shariati‐Sarabi, Z., Tavakkol‐Afshari, J. and Mohammadi, M. (2019) The Role of BAFF and APRIL in Rheumatoid Arthritis. Journal of Cellular Physiology, 234, 17050-17063. [Google Scholar] [CrossRef] [PubMed]
[37] Mathur, M., Barratt, J., Chacko, B., Chan, T.M., Kooienga, L., Oh, K., et al. (2024) A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. New England Journal of Medicine, 390, 20-31. [Google Scholar] [CrossRef] [PubMed]
[38] Barratt, J., Workeneh, B., Kim, S.G., Lee, E.Y., Lam, C., Sorensen, B., et al. (2025) WCN25-1585 a Phase 1/2 Trial of Zigakibart in Iga Nephropathy (IgAN). Kidney International Reports, 10, S769-S770. [Google Scholar] [CrossRef] 
[39] Lv, J., Liu, L., Hao, C., Li, G., Fu, P., Xing, G., et al. (2023) Randomized Phase 2 Trial of Telitacicept in Patients with IgA Nephropathy with Persistent Proteinuria. Kidney International Reports, 8, 499-506. [Google Scholar] [CrossRef] [PubMed]
[40] Barratt, J., Tumlin, J., Suzuki, Y., Kao, A., Aydemir, A., Pudota, K., et al. (2022) Randomized Phase II JANUS Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Kidney International Reports, 7, 1831-1841. [Google Scholar] [CrossRef] [PubMed]
[41] Lafayette, R.A., Canetta, P.A., Rovin, B.H., Appel, G.B., Novak, J., Nath, K.A., et al. (2016) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology, 28, 1306-1313. [Google Scholar] [CrossRef] [PubMed]
[42] Patel, U., Flöge, J., Barratt, J., Lafayette, R., Schwartz, B., Manser, P., et al. (2025) WCN25-844 Felzartamab for IgA Nephropathy: Final Results of the Ignaz Study. Kidney International Reports, 10, S185. [Google Scholar] [CrossRef] 
[43] Frisch, G., Lin, J., Rosenstock, J., Markowitz, G., D’Agati, V., Radhakrishnan, J., et al. (2005) Mycophenolate Mofetil (MMF) vs Placebo in Patients with Moderately Advanced IgA Nephropathy: A Double-Blind Randomized Controlled Trial. Nephrology Dialysis Transplantation, 20, 2139-2145. [Google Scholar] [CrossRef] [PubMed]
[44] Maes, B.D., Oyen, R., Claes, K., Evenepoel, P., Kuypers, D., Vanwalleghem, J., et al. (2004) Mycophenolate Mofetil in IgA Nephropathy: Results of a 3-Year Prospective Placebo-Controlled Randomized Study. Kidney International, 65, 1842-1849. [Google Scholar] [CrossRef] [PubMed]
[45] Tang, S.C.W., Tang, A.W.C., Wong, S.S.H., Leung, J.C.K., Ho, Y.W. and Lai, K.N. (2010) Long-Term Study of Mycophenolate Mofetil Treatment in Iga Nephropathy. Kidney International, 77, 543-549. [Google Scholar] [CrossRef] [PubMed]

为你推荐